Treatment of anemia with darbepoetin alfa in systolic heart failure - The New England Journal of Medicine - 2013
Brief Summary:
Among patients with LV systolic dysfunction and mild to moderate anemia, the use of darbepoetin targeting a hemoglobin >13 g/dL does not reduce the composite outcome of all-cause mortality or first hospitalization for HF.Reference: http://www.ncbi.nlm.nih.gov/pubmed/23473338
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you